CytomX(US:CTMX) Benzingaยท2025-05-12 15:11Core Insights - CytomX Therapeutics, Inc. experienced a significant stock price increase of 94.46% following the announcement of interim Phase 1 data for its EpCAM PROBODY ADC candidate, CX-2051, in advanced colorectal cancer [1] Clinical Data Summary - As of April 7, 25 advanced metastatic colorectal cancer patients were treated with CX-2051 across five dose levels, administered every three weeks [1] - A confirmed partial overall response rate (ORR) of 28% was observed, with 5 out of 18 patients achieving this response [2] - The median progression-free survival was reported at 5.8 months, with 10 out of 18 patients remaining on study treatment at the data cutoff [3] - CX-2051 was generally well-tolerated, with manageable adverse events and no dose-limiting toxicities observed; most treatment-related adverse events were Grade 1 or Grade 2 in severity [3] - The company has initiated dose expansions at 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg, with plans to enroll 20 patients at each level to determine the recommended Phase 2 dose [3] - Additional Phase 1 data for CX-2051 monotherapy is expected by Q1 2026, with a Phase 2 study planned for the first half of 2026 [3] Future Development Plans - CytomX plans to initiate combination studies of CX-2051 in earlier lines of colorectal cancer in 2026 [4] - The company also aims to evaluate CX-2051 in non-colorectal, EpCAM-expressing tumor indications, with potential Phase 1b study initiation in 2026 [4] Financial Overview - CytomX priced an underwritten offering of approximately 76.92 million shares at $1.30 per share, raising $100 million in gross proceeds [4] - Focused clinical development priorities and cost reductions have extended the company's cash runway into Q2 2026, ending the quarter with $79.9 million in cash, cash equivalents, and investments [5]